Transfer of Non-Core Products to Focus on Neonatal

Inspiration Healthcare Group PLC

02 June 2026

 

2 June 2026

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

Transfer of Non-Core Distributed Products to Focus on Neonatal

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company, announces that on 1 June 2026 it entered into a framework agreement with Micrel Medical Devices SA ("Micrel") for the transfer of the distribution of Micrel's infusion products to an entity controlled by Micrel effective from 31 January 2027.

The Group has been the exclusive distributor of Micrel's ambulatory infusion pumps and related consumables in the United Kingdom since 2011. During this time Inspiration Healthcare has built a market leading position in the homecare market for parenteral nutrition and a growing presence in the NHS. The infusion products generated revenue of £9.7million (unaudited) at a contribution margin of approximately 25% for the Group in the year ended 31 January 2026.

Under the terms of the framework agreement, the existing distribution agreement will expire on 31 January 2027 with Micrel taking full control for the sale and distribution of the products in the UK.  The Inspiration Healthcare employees responsible for the infusion products will transfer to Micrel under TUPE from 1 July 2026. In addition, Micrel will buy back unsold inventory on the final transfer date and make a compensation payment to Inspiration Healthcare in exchange for the orderly transition of the business and reflecting the goodwill generated during Inspiration's tenure as UK distributor.

Inspiration Healthcare will continue to manage and sell the products during a transition period until 31 January 2027 meaning there will be no impact on the Group's revenue and gross profit estimates for the current financial year. The transfer of employees to Micrel on 1 July will generate savings in operating expenses in the second half. The Board expects these savings, combined with the compensation payment, to contribute to reducing net debt by approximately 20% during FY27*.

Raffi Stepanian, CEO of Inspiration Healthcare commented: "This separation of the infusion products allows the Group to focus on its core business of neonatology and neonatal ventilation in particular. The Group has identified opportunities to grow its product portfolio and footprint in this segment through organic means as well as third party distribution opportunities and continues to assess further opportunities."

*As at 31 January 2026, net debt (excluding IFRS16 lease liabilities) stood at £5.1m

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

For further information, please contact:

Inspiration Healthcare Group plc			Tel: [phone]
Raffi Stepanian, Chief Executive Officer
Alan Olby, Chief Financial Officer
Singer Capital Markets (Nominated Adviser & Broker)						Tel: [phone]
Alex Bond
Jalini Kalaravy
Cavendish Capital Markets (Joint Broker)				Tel: + 44 (0)20 7220 0500
Giles Balleny / Joe Smith
Nigel Birks
Harriet Ward
Walbrook PR Ltd (Media & IR)	Tel: [phone] or [e-mail]
Anna Dunphy			Mob: [phone]
Rachel Broad			Mob: [phone]

About Inspiration Healthcare

Inspiration Healthcare (AIM: IHC) designs, manufactures and markets pioneering medical technology. Based in the UK, the Company specialises in neonatal intensive care medical devices, which are addressing a critical need to help to save the lives and improve the outcomes of patients, starting with the very first breaths of life.

The Company has a broad portfolio of its own products and complementary distributed products, for use in neonatal intensive care designed to support even the most premature babies throughout their hospital stay. Its own branded products range from highly sophisticated capital equipment such as ventilators for life support through to single-use disposables.

The Company sells its products directly to hospitals and healthcare providers in the UK and Ireland, where it also distributes a range of advanced medical technologies for infusion therapy. In the rest of the world the Company has an established network of distribution partners around the world giving access to more than 75 countries.

The Company operates in the UK from its world-class Manufacturing and Technology Centre in Croydon, South London and in the USA from its facility in Melbourne, Florida.

Further information on Inspiration Healthcare can be found at www.inspirationhealthcaregroup.com

 

END